Glenmark Gets USFDA Approval for Generic Ophthalmic Solution
May 17, 2024 09:49
Glenmark Pharmaceuticals receives USFDA approval for its generic brimonidine tartrate and timolol maleate ophthalmic solution for treating increased eye pressure caused by glaucoma.
New Delhi, May 17 (PTI) Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions.
The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement.
The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added.
The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added.
Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data for the 12-month period ended March 2024.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.